Preferred Label : Nirmatrelvir/Ritonavir;
NCIt synonyms : Ritonavir/Nirmatrelvir;
NCIt related terms : SARS-CoV-2 protease inhibitors: nirmatrelvir/ritonavir;
NCIt definition : A fixed combination of nirmatrelvir, an inhibitor of the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro; 3C-like protease; 3CL protease;
3CLpro; nsp5 protease), and ritonavir, an inhibitor of cytochrome P450 3A4 (CYP3A4),
that may be used to treat coronavirus disease 2019 (COVID-19). Upon oral administration
of nirmatrelvir/ritonavir, nirmatrelvir selectively targets, binds to, and inhibits
the activity of SARS-CoV-2 Mpro. This inhibits the proteolytic cleavage of viral polyproteins,
thereby inhibiting the formation of viral proteins including helicase, single-stranded-RNA-binding
protein, RNA-dependent RNA polymerase, 20-O-ribose methyltransferase, endoribonuclease
and exoribonuclease. This prevents viral transcription and replication. Ritonavir
inhibits CYP3A4-mediated metabolism of nirmatrelvir, thereby increasing the plasma
concentration of nirmatrelvir.;
Alternative definition : ACC/AHA: Nirmatrelvir inhibits the SARS-CoV-2 main protease (Mpro), which results
in inhibition of viral replication. Ritonavir has no direct activity against SARS-CoV-2
but is a pharmacokinetic boosting agent that results in higher plasma concentrations
of nirmatrelvir.;
Drug name : Paxlovid;
NCI Metathesaurus CUI : CL1793033;
Origin ID : C188303;
UMLS CUI : C5564905;
CISMeF manual mappings
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/usage-optimal-du-nirmatrelvir-ritonavir-paxlovidmc.html
2023
Canada
guidelines for drug use
Nirmatrelvir/Ritonavir
Paxlovid
Usage
Optimum
---
